Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.
Identifieur interne : 000103 ( PubMed/Curation ); précédent : 000102; suivant : 000104Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.
Auteurs : Irina Isakova-Sivak [États-Unis] ; Li-Mei Chen ; Melissa Bourgeois ; Yumiko Matsuoka ; J Theo M. Voeten ; Jacco G M. Heldens ; Han Van Den Bosch ; Alexander Klimov ; Larisa Rudenko ; Nancy J. Cox ; Ruben O. DonisSource :
- Clinical and vaccine immunology : CVI [ 1556-679X ] ; 2014.
Descripteurs français
- KwdFr :
- Analyse de survie, Animaux, Anticorps antiviraux (sang), Femelle, Glycoprotéine hémagglutinine du virus influenza (génétique), Glycoprotéine hémagglutinine du virus influenza (immunologie), Génétique inverse, Immunoglobuline A (sang), Infections à Orthomyxoviridae (), Modèles animaux de maladie humaine, Protéines virales (génétique), Protéines virales (immunologie), Sialidase (génétique), Sialidase (immunologie), Souris de lignée BALB C, Sous-type H2N2 du virus de la grippe A (génétique), Sous-type H2N2 du virus de la grippe A (immunologie), Sous-type H5N1 du virus de la grippe A (génétique), Sous-type H5N1 du virus de la grippe A (immunologie), Structures anatomiques de l'animal (virologie), Vaccination (), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (génétique), Vaccins antigrippaux (immunologie), Vaccins atténués (administration et posologie), Vaccins atténués (génétique), Vaccins atténués (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (génétique), Vaccins synthétiques (immunologie), Virulence, Virus recombinants (génétique), Virus recombinants (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins atténués, Vaccins synthétiques.
- génétique : Glycoprotéine hémagglutinine du virus influenza, Protéines virales, Sialidase, Sous-type H2N2 du virus de la grippe A, Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux, Vaccins atténués, Vaccins synthétiques, Virus recombinants.
- immunologie : Glycoprotéine hémagglutinine du virus influenza, Protéines virales, Sialidase, Sous-type H2N2 du virus de la grippe A, Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux, Vaccins atténués, Vaccins synthétiques, Virus recombinants.
- sang : Anticorps antiviraux, Immunoglobuline A.
- virologie : Structures anatomiques de l'animal.
- Analyse de survie, Animaux, Femelle, Génétique inverse, Infections à Orthomyxoviridae, Modèles animaux de maladie humaine, Souris de lignée BALB C, Vaccination, Virulence.
English descriptors
- KwdEn :
- Animal Structures (virology), Animals, Antibodies, Viral (blood), Disease Models, Animal, Female, Hemagglutinin Glycoproteins, Influenza Virus (genetics), Hemagglutinin Glycoproteins, Influenza Virus (immunology), Immunoglobulin A (blood), Influenza A Virus, H2N2 Subtype (genetics), Influenza A Virus, H2N2 Subtype (immunology), Influenza A Virus, H5N1 Subtype (genetics), Influenza A Virus, H5N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Mice, Inbred BALB C, Neuraminidase (genetics), Neuraminidase (immunology), Orthomyxoviridae Infections (prevention & control), Reassortant Viruses (genetics), Reassortant Viruses (immunology), Reverse Genetics, Survival Analysis, Vaccination (methods), Vaccines, Attenuated (administration & dosage), Vaccines, Attenuated (genetics), Vaccines, Attenuated (immunology), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (genetics), Vaccines, Synthetic (immunology), Viral Proteins (genetics), Viral Proteins (immunology), Virulence.
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Attenuated, Vaccines, Synthetic.
- chemical , blood : Antibodies, Viral, Immunoglobulin A.
- chemical , genetics : Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Neuraminidase, Vaccines, Attenuated, Vaccines, Synthetic, Viral Proteins.
- chemical , immunology : Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Neuraminidase, Vaccines, Attenuated, Vaccines, Synthetic, Viral Proteins.
- genetics : Influenza A Virus, H2N2 Subtype, Influenza A Virus, H5N1 Subtype, Reassortant Viruses.
- immunology : Influenza A Virus, H2N2 Subtype, Influenza A Virus, H5N1 Subtype, Reassortant Viruses.
- methods : Vaccination.
- prevention & control : Orthomyxoviridae Infections.
- virology : Animal Structures.
- Animals, Disease Models, Animal, Female, Mice, Inbred BALB C, Reverse Genetics, Survival Analysis, Virulence.
Abstract
Live attenuated influenza vaccines (LAIV) offer significant advantages over subunit or split inactivated vaccines to mitigate an eventual influenza pandemic, including simpler manufacturing processes and more cross-protective immune responses. Using an established reverse genetics (rg) system for wild-type (wt) A/Leningrad/134/1957 and cold-adapted (ca) A/Leningrad/134/17/1957 (Len17) master donor virus (MDV), we produced and characterized three rg H5N1 reassortant viruses carrying modified HA and intact NA genes from either A/Vietnam/1203/2004 (H5N1, VN1203, clade 1) or A/Egypt/321/2007 (H5N1, EG321, clade 2) virus. A mouse model of infection was used to determine the infectivity and tissue tropism of the parental wt viruses compared to the ca master donor viruses as well as the H5N1 reassortants. All ca viruses showed reduced replication in lungs and enhanced replication in nasal epithelium. In addition, the H5N1 HA and NA enhanced replication in lungs unless it was restricted by the internal genes of the ca MDV. Mice inoculated twice 4 weeks apart with the H5N1 reassortant LAIV candidate viruses developed serum hemagglutination inhibition HI and IgA antibody titers to the homologous and heterologous viruses consistent with protective immunity. These animals remained healthy after challenge inoculation with a lethal dose with homologous or heterologous wt H5N1 highly pathogenic avian influenza (HPAI) viruses. The profiles of viral replication in respiratory tissues and the immunogenicity and protective efficacy characteristics of the two ca H5N1 candidate LAIV viruses warrant further development into a vaccine for human use.
DOI: 10.1128/CVI.00819-13
PubMed: 24648485
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000103
Links to Exploration step
pubmed:24648485Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.</title>
<author><name sortKey="Isakova Sivak, Irina" sort="Isakova Sivak, Irina" uniqKey="Isakova Sivak I" first="Irina" last="Isakova-Sivak">Irina Isakova-Sivak</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chen, Li Mei" sort="Chen, Li Mei" uniqKey="Chen L" first="Li-Mei" last="Chen">Li-Mei Chen</name>
</author>
<author><name sortKey="Bourgeois, Melissa" sort="Bourgeois, Melissa" uniqKey="Bourgeois M" first="Melissa" last="Bourgeois">Melissa Bourgeois</name>
</author>
<author><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name>
</author>
<author><name sortKey="Voeten, J Theo M" sort="Voeten, J Theo M" uniqKey="Voeten J" first="J Theo M" last="Voeten">J Theo M. Voeten</name>
</author>
<author><name sortKey="Heldens, Jacco G M" sort="Heldens, Jacco G M" uniqKey="Heldens J" first="Jacco G M" last="Heldens">Jacco G M. Heldens</name>
</author>
<author><name sortKey="Van Den Bosch, Han" sort="Van Den Bosch, Han" uniqKey="Van Den Bosch H" first="Han" last="Van Den Bosch">Han Van Den Bosch</name>
</author>
<author><name sortKey="Klimov, Alexander" sort="Klimov, Alexander" uniqKey="Klimov A" first="Alexander" last="Klimov">Alexander Klimov</name>
</author>
<author><name sortKey="Rudenko, Larisa" sort="Rudenko, Larisa" uniqKey="Rudenko L" first="Larisa" last="Rudenko">Larisa Rudenko</name>
</author>
<author><name sortKey="Cox, Nancy J" sort="Cox, Nancy J" uniqKey="Cox N" first="Nancy J" last="Cox">Nancy J. Cox</name>
</author>
<author><name sortKey="Donis, Ruben O" sort="Donis, Ruben O" uniqKey="Donis R" first="Ruben O" last="Donis">Ruben O. Donis</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24648485</idno>
<idno type="pmid">24648485</idno>
<idno type="doi">10.1128/CVI.00819-13</idno>
<idno type="wicri:Area/PubMed/Corpus">000103</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000103</idno>
<idno type="wicri:Area/PubMed/Curation">000103</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000103</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.</title>
<author><name sortKey="Isakova Sivak, Irina" sort="Isakova Sivak, Irina" uniqKey="Isakova Sivak I" first="Irina" last="Isakova-Sivak">Irina Isakova-Sivak</name>
<affiliation wicri:level="1"><nlm:affiliation>Influenza Division, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Division, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chen, Li Mei" sort="Chen, Li Mei" uniqKey="Chen L" first="Li-Mei" last="Chen">Li-Mei Chen</name>
</author>
<author><name sortKey="Bourgeois, Melissa" sort="Bourgeois, Melissa" uniqKey="Bourgeois M" first="Melissa" last="Bourgeois">Melissa Bourgeois</name>
</author>
<author><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name>
</author>
<author><name sortKey="Voeten, J Theo M" sort="Voeten, J Theo M" uniqKey="Voeten J" first="J Theo M" last="Voeten">J Theo M. Voeten</name>
</author>
<author><name sortKey="Heldens, Jacco G M" sort="Heldens, Jacco G M" uniqKey="Heldens J" first="Jacco G M" last="Heldens">Jacco G M. Heldens</name>
</author>
<author><name sortKey="Van Den Bosch, Han" sort="Van Den Bosch, Han" uniqKey="Van Den Bosch H" first="Han" last="Van Den Bosch">Han Van Den Bosch</name>
</author>
<author><name sortKey="Klimov, Alexander" sort="Klimov, Alexander" uniqKey="Klimov A" first="Alexander" last="Klimov">Alexander Klimov</name>
</author>
<author><name sortKey="Rudenko, Larisa" sort="Rudenko, Larisa" uniqKey="Rudenko L" first="Larisa" last="Rudenko">Larisa Rudenko</name>
</author>
<author><name sortKey="Cox, Nancy J" sort="Cox, Nancy J" uniqKey="Cox N" first="Nancy J" last="Cox">Nancy J. Cox</name>
</author>
<author><name sortKey="Donis, Ruben O" sort="Donis, Ruben O" uniqKey="Donis R" first="Ruben O" last="Donis">Ruben O. Donis</name>
</author>
</analytic>
<series><title level="j">Clinical and vaccine immunology : CVI</title>
<idno type="eISSN">1556-679X</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal Structures (virology)</term>
<term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (genetics)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term>
<term>Immunoglobulin A (blood)</term>
<term>Influenza A Virus, H2N2 Subtype (genetics)</term>
<term>Influenza A Virus, H2N2 Subtype (immunology)</term>
<term>Influenza A Virus, H5N1 Subtype (genetics)</term>
<term>Influenza A Virus, H5N1 Subtype (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (genetics)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Mice, Inbred BALB C</term>
<term>Neuraminidase (genetics)</term>
<term>Neuraminidase (immunology)</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Reassortant Viruses (genetics)</term>
<term>Reassortant Viruses (immunology)</term>
<term>Reverse Genetics</term>
<term>Survival Analysis</term>
<term>Vaccination (methods)</term>
<term>Vaccines, Attenuated (administration & dosage)</term>
<term>Vaccines, Attenuated (genetics)</term>
<term>Vaccines, Attenuated (immunology)</term>
<term>Vaccines, Synthetic (administration & dosage)</term>
<term>Vaccines, Synthetic (genetics)</term>
<term>Vaccines, Synthetic (immunology)</term>
<term>Viral Proteins (genetics)</term>
<term>Viral Proteins (immunology)</term>
<term>Virulence</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de survie</term>
<term>Animaux</term>
<term>Anticorps antiviraux (sang)</term>
<term>Femelle</term>
<term>Glycoprotéine hémagglutinine du virus influenza (génétique)</term>
<term>Glycoprotéine hémagglutinine du virus influenza (immunologie)</term>
<term>Génétique inverse</term>
<term>Immunoglobuline A (sang)</term>
<term>Infections à Orthomyxoviridae ()</term>
<term>Modèles animaux de maladie humaine</term>
<term>Protéines virales (génétique)</term>
<term>Protéines virales (immunologie)</term>
<term>Sialidase (génétique)</term>
<term>Sialidase (immunologie)</term>
<term>Souris de lignée BALB C</term>
<term>Sous-type H2N2 du virus de la grippe A (génétique)</term>
<term>Sous-type H2N2 du virus de la grippe A (immunologie)</term>
<term>Sous-type H5N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H5N1 du virus de la grippe A (immunologie)</term>
<term>Structures anatomiques de l'animal (virologie)</term>
<term>Vaccination ()</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (génétique)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins atténués (administration et posologie)</term>
<term>Vaccins atténués (génétique)</term>
<term>Vaccins atténués (immunologie)</term>
<term>Vaccins synthétiques (administration et posologie)</term>
<term>Vaccins synthétiques (génétique)</term>
<term>Vaccins synthétiques (immunologie)</term>
<term>Virulence</term>
<term>Virus recombinants (génétique)</term>
<term>Virus recombinants (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
<term>Vaccines, Synthetic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Neuraminidase</term>
<term>Vaccines, Attenuated</term>
<term>Vaccines, Synthetic</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Influenza Vaccines</term>
<term>Neuraminidase</term>
<term>Vaccines, Attenuated</term>
<term>Vaccines, Synthetic</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
<term>Vaccins synthétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
<term>Influenza A Virus, H5N1 Subtype</term>
<term>Reassortant Viruses</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Protéines virales</term>
<term>Sialidase</term>
<term>Sous-type H2N2 du virus de la grippe A</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
<term>Vaccins synthétiques</term>
<term>Virus recombinants</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Protéines virales</term>
<term>Sialidase</term>
<term>Sous-type H2N2 du virus de la grippe A</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
<term>Vaccins synthétiques</term>
<term>Virus recombinants</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
<term>Influenza A Virus, H5N1 Subtype</term>
<term>Reassortant Viruses</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Immunoglobuline A</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Structures anatomiques de l'animal</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Animal Structures</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Mice, Inbred BALB C</term>
<term>Reverse Genetics</term>
<term>Survival Analysis</term>
<term>Virulence</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term>
<term>Animaux</term>
<term>Femelle</term>
<term>Génétique inverse</term>
<term>Infections à Orthomyxoviridae</term>
<term>Modèles animaux de maladie humaine</term>
<term>Souris de lignée BALB C</term>
<term>Vaccination</term>
<term>Virulence</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Live attenuated influenza vaccines (LAIV) offer significant advantages over subunit or split inactivated vaccines to mitigate an eventual influenza pandemic, including simpler manufacturing processes and more cross-protective immune responses. Using an established reverse genetics (rg) system for wild-type (wt) A/Leningrad/134/1957 and cold-adapted (ca) A/Leningrad/134/17/1957 (Len17) master donor virus (MDV), we produced and characterized three rg H5N1 reassortant viruses carrying modified HA and intact NA genes from either A/Vietnam/1203/2004 (H5N1, VN1203, clade 1) or A/Egypt/321/2007 (H5N1, EG321, clade 2) virus. A mouse model of infection was used to determine the infectivity and tissue tropism of the parental wt viruses compared to the ca master donor viruses as well as the H5N1 reassortants. All ca viruses showed reduced replication in lungs and enhanced replication in nasal epithelium. In addition, the H5N1 HA and NA enhanced replication in lungs unless it was restricted by the internal genes of the ca MDV. Mice inoculated twice 4 weeks apart with the H5N1 reassortant LAIV candidate viruses developed serum hemagglutination inhibition HI and IgA antibody titers to the homologous and heterologous viruses consistent with protective immunity. These animals remained healthy after challenge inoculation with a lethal dose with homologous or heterologous wt H5N1 highly pathogenic avian influenza (HPAI) viruses. The profiles of viral replication in respiratory tissues and the immunogenicity and protective efficacy characteristics of the two ca H5N1 candidate LAIV viruses warrant further development into a vaccine for human use.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24648485</PMID>
<DateCompleted><Year>2014</Year>
<Month>12</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-679X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>21</Volume>
<Issue>5</Issue>
<PubDate><Year>2014</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Clinical and vaccine immunology : CVI</Title>
<ISOAbbreviation>Clin. Vaccine Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.</ArticleTitle>
<Pagination><MedlinePgn>722-31</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/CVI.00819-13</ELocationID>
<Abstract><AbstractText>Live attenuated influenza vaccines (LAIV) offer significant advantages over subunit or split inactivated vaccines to mitigate an eventual influenza pandemic, including simpler manufacturing processes and more cross-protective immune responses. Using an established reverse genetics (rg) system for wild-type (wt) A/Leningrad/134/1957 and cold-adapted (ca) A/Leningrad/134/17/1957 (Len17) master donor virus (MDV), we produced and characterized three rg H5N1 reassortant viruses carrying modified HA and intact NA genes from either A/Vietnam/1203/2004 (H5N1, VN1203, clade 1) or A/Egypt/321/2007 (H5N1, EG321, clade 2) virus. A mouse model of infection was used to determine the infectivity and tissue tropism of the parental wt viruses compared to the ca master donor viruses as well as the H5N1 reassortants. All ca viruses showed reduced replication in lungs and enhanced replication in nasal epithelium. In addition, the H5N1 HA and NA enhanced replication in lungs unless it was restricted by the internal genes of the ca MDV. Mice inoculated twice 4 weeks apart with the H5N1 reassortant LAIV candidate viruses developed serum hemagglutination inhibition HI and IgA antibody titers to the homologous and heterologous viruses consistent with protective immunity. These animals remained healthy after challenge inoculation with a lethal dose with homologous or heterologous wt H5N1 highly pathogenic avian influenza (HPAI) viruses. The profiles of viral replication in respiratory tissues and the immunogenicity and protective efficacy characteristics of the two ca H5N1 candidate LAIV viruses warrant further development into a vaccine for human use.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Isakova-Sivak</LastName>
<ForeName>Irina</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Influenza Division, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, Georgia, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Li-Mei</ForeName>
<Initials>LM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bourgeois</LastName>
<ForeName>Melissa</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Matsuoka</LastName>
<ForeName>Yumiko</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Voeten</LastName>
<ForeName>J Theo M</ForeName>
<Initials>JT</Initials>
</Author>
<Author ValidYN="Y"><LastName>Heldens</LastName>
<ForeName>Jacco G M</ForeName>
<Initials>JG</Initials>
</Author>
<Author ValidYN="Y"><LastName>van den Bosch</LastName>
<ForeName>Han</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Klimov</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rudenko</LastName>
<ForeName>Larisa</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cox</LastName>
<ForeName>Nancy J</ForeName>
<Initials>NJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Donis</LastName>
<ForeName>Ruben O</ForeName>
<Initials>RO</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>03</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Vaccine Immunol</MedlineTA>
<NlmUniqueID>101252125</NlmUniqueID>
<ISSNLinking>1556-679X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="C487630">NA protein, influenza A virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000825" MajorTopicYN="N">Animal Structures</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053121" MajorTopicYN="N">Influenza A Virus, H2N2 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016865" MajorTopicYN="N">Reassortant Viruses</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D059386" MajorTopicYN="N">Reverse Genetics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>3</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>12</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24648485</ArticleId>
<ArticleId IdType="pii">CVI.00819-13</ArticleId>
<ArticleId IdType="doi">10.1128/CVI.00819-13</ArticleId>
<ArticleId IdType="pmc">PMC4018889</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Virology. 2011 Apr 10;412(2):297-305</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21315402</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2010 Sep;155(9):1391-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20532926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2011 Aug;10(8):1183-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21854311</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2011 Nov 15;204(10):1491-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21957153</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(1):e30252</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22279575</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Feb 8;30(7):1388-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22192847</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2012 Mar;6(2):90-100</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21749672</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2012 May;86(9):5089-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22379093</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2012 May;86(10):5953-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22438541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Appl Microbiol Biotechnol. 2012 Jun;94(5):1173-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22415544</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2012 May;11(5):587-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22827244</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(12):e15559</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21203523</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10801978</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2001 Sep;65(1):171-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11505460</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2003 Jan 5;305(1):192-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12504552</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Scand J Immunol. 2004 Jan;59(1):1-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14723616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2004 Jul;103(1-2):91-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163495</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vopr Virusol. 1965 Jan-Feb;10(1):67-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5865829</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 1986 Jan;23(1):66-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3700610</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vopr Virusol. 1986 Jul-Aug;31(4):411-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2945324</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vopr Virusol. 1991 Nov-Dec;36(6):472-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1785181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1993 Oct;168(4):881-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8376833</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1995 Jun;76 ( Pt 6):1521-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7782782</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 1996;74(1):77-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8653819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2004 Dec;3(6):643-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15606348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet Rec. 2005 Aug 6;157(6):159-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16085721</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Jpn J Infect Dis. 2005 Aug;58(4):195-207</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16116250</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2005 Oct;11(10):1515-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16318689</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Nov 10;24(44-46):6588-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17030078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Nov 17;24(47-48):6859-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17050041</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e360</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2007 Jan 15;178(2):1030-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17202366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Rev. 2007 Apr;20(2):243-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17428885</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2008 Jan 17;358(3):261-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18199865</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 Feb;82(3):1350-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18032492</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2008 May;4(5):e1000072</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18497857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009;4(2):e4436</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19209231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2009 Apr;8(4):401-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19348557</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Protoc Microbiol. 2009 May;Chapter 15:Unit 15G.3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19412911</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2008 Nov;2(6):203-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19453396</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Jun 8;27(28):3744-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19464558</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Aug;83(16):8131-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19493997</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Aug 6;27(36):4953-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19540952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2010 Mar 12;85(11):100-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20229648</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Avian Dis. 2010 Mar;54(1 Suppl):329-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20521654</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Oct;84(20):10918-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20686037</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Rev Microbiol. 2011 May;37(2):157-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21438845</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000103 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000103 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:24648485 |texte= Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24648485" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |